|
Select publications
Arpino G et al. Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition. San Antonio Breast Cancer Symposium, 2004;Abstract 23.
Badache A, Hynes NE. A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 2004;5(4):299-301. Abstract
Blackwell KL et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab refractory metastatic breast cancer. Proc ASCO 2004;Abstract 3006.
Buzdar AU et al. Significantly higher pathological complete remission rate following neoadjuvant therapy with trastuzumab [Herceptin (H)], paclitaxel (P), and anthracycline containing chemotherapy: Initial results of a randomized trial in operable breast cancer with HER-2 positive disease. Proc ASCO 2004;Abstract 520.
Chang JC et al. Induction of apoptosis without change in cell proliferation in primary breast cancers with neoadjuvant trastuzumab. San Antonio Breast Cancer Symposium, 2003a;Abstract 24.
Chang JC et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003b;362(9381):362-9. Abstract
Gelmon KA et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin Breast Cancer 2004;5(1):52-8. Abstract
Kostler WJ et al. Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: A single-institution experience. Anticancer Drugs 2005;16(2):185-190. Abstract
Nahta R et al. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004;64(7):2343-6. Abstract
Pegram MD et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96(10):739-49. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2- overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
|
